IBRX Bulls Shrug Off Earnings Loss -- Retail Traders Eye A Crucial FDA Deadline

• The growth was driven by a 168% increase in sales of its flagship immunotherapy, Anktiva.
• First-quarter net loss came in at $0.62 per share, compared to Street estimates of $0.07 per share.
• ImmunityBio said the wider net loss was mainly due to changes in the value of warrants and derivative liabilities. 

Retail favorite ImmunityBio (IBRX) was back in the spotlight on Thursday after posting first-quarter earnings, as investors shrugged off a 6% pre-market dip and continued piling into the stock with bullish conviction.

IBRX shares could snap a six-session winning streak if the stock stays at current levels through Thursday’s close.

Anktiva Drives IBRX’s Q1 Sales Though Loss Widens

ImmunityBio posted a 168% jump in first-quarter (Q1) net sales to $44.2 million, in line with its own expectations, but marginally beating Wall Street’s estimates of $43.9 million, according to Fiscal.ai data.

The growth was driven by a 168% increase in sales of its flagship immunotherapy, Anktiva. The drug is approved or authorized in 34 countries across five regulatory regions.

The results add to FY2025 net product revenue of $113 million, up 700% from 2024, and 15% from the fourth quarter (Q4) of 2025. The company also reported $380.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026, compared to $242.8 million as of Dec. 31, 2025.

However, net loss widened significantly to $632.8 million, or $0.62 per share, compared to a loss of $129.6 million, or $0.15 per share. Analysts on average forecast a loss of $0.07 per share. ImmunityBio said the wider net loss was mainly due to changes in the value of warrants and derivative liabilities, as well as a convertible note tied to a related-party transaction.

Retail Dismisses IBRX’s Slide

Despite the pre-market decline, retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, while message volumes remained ‘high.’

One user sounded positive on the firm’s prospects.

Another user urged investors to ignore the EPS headline, adding that the “fundamentals are primed” for the FDA deadline.

The FDA’s 60-day review window for the resubmitted supplemental biologics license application (sBLA) for Anktiva expires on Thursday. The filing includes long-term data showing 58.2% of patients remained cancer-free at one year, while more than 80% avoided bladder removal surgery over three years.

The stock has gained around 295% so far this year.

Read also: Peter Brandt Says Silver Could Be Setting Up For Next Leg Of Rally – HL, PAAS, AG Stocks Pop Pre-Market

For updates and corrections, email newsroom[at]stocktwits[dot]com.